ARCHIVES

Study Tests PARP Inhibitor ABT-888 For Several Cancers

This article is from The Cancer Letter archive.

Vol. 32 No. 9 | September 25, 2009

Download PDF Visit The Full Archive

Related Articles

Amgen Replaces “Bundling” Contract With Three Separate Contracts For Growth Factors.

September 5, 2008

NCAB Votes Down Effort to Delay CCOP RFA, Directs Subcommittee To Look Again A Program Components

February 12, 1982

Q&A: Data that Killed CYP2D6 Testing Contradict Fundamental Law of Nature

May 18, 2012

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

Five Advocates Named To SWOG Committees; NCI, NASA Sign Nanotechnology Agreement.

April 21, 2000

Nine New Grants Awarded In The NCI “Director’s Challenge”.

October 13, 2000